Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor EL
Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs
Known intolerance to either of the study drugs (or any of the excipients)
Allergy or hypersensitivity to cemiplimab or to any of its excipients;
Hypersensitivity to nivolumab, ipilimumab, or any of their excipients
Known allergy or hypersensitivity to any of the study drugs or their excipients.
History of allergy or hypersensitivity to any study drugs or their excipients
Known hypersensitivity to any of the excipients of ribociclib
History of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs.
Subject with a history of severe hypersensitivity reactions to any of the other excipients of the protocol IMPs (see Section 8.1.1);
Hypersensitivity to the active substance or to any of the excipients
Patient has a known hypersensitivity to any of the excipients of LEE011
Known hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipients
Known hypersensitivity to sunitinib or masitinib or to any of the excipients
Patients who have had hypersensitivity to paclitaxel or any of its excipients
Has a known severe hypersensitivity (? Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.
Have previously participated in any study involving a checkpoint kinase 1 inhibitor or have hypersensitivity to the study drug or excipients.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Known hypersensitivity to exemestane or its excipients
Hypersensitivity to nivolumab or any of its excipients.
Hypersensitivity to NKTR-214 or any of its excipients.
Participant has a known hypersensitivity to any of the excipients of H3B-6545.
Patient has a known hypersensitivity to any of the excipients of ribociclib or everolimus
Subjects with known allergies, hypersensitivity, or intolerance to niraparib or its excipients
Patient has a known hypersensitivity to any of the excipients of LEE011 or everolimus
Known hypersensitivity to afatinib or the excipients of any of the trial drugs
Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red.
History of severe hypersensitivity to study treatment excipients and additives or other monoclonal antibodies (mAbs) and/or their excipients.
Porphyria or known hypersensitivity to PhotofrinÂ® or porphyrin-like compounds or to any of its excipients
Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)
Prior known hypersensitivity to any of the excipients of alpelisib
Known history, or suspected hypersensitivity to any excipients.
Known hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator Brochure
Any known hypersensitivity to bevacizumab, erlotinib or other excipients of these drugs
EXCLUSION - PARTICIPANT: Participants with a history of hypersensitivity reactions to study agent or their excipients.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Participants must not have hypersensitivity to nivolumab, urelumab, cabiralizumab or any of their excipients
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Has severe hypersensitivity (?Grade 3) to any study therapies including any excipients
Hypersensitivity to Ipilimumab and/or nivolumab or any of its excipients
Known hypersensitivity to gemcitabine (or other drug excipients) or chemically related drugs.
Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
Known intolerance or hypersensitivity to any of the products used in this study or their excipients.
Subjects with known hypersensitivity to study drugs or their excipients
Known hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their excipients
Known allergy or hypersensitivity to any of the study drugs or any of their excipients
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Hypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or its formulation excipients
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Hypersensitivity to ipilimumab or nivolumab or any of their excipients
Hypersensitivity to PBZ or any of its excipients
Has hypersensitivity to either study drug or any of the excipients.
Hypersensitivity to nivolumab, ipilimumab, or any of its excipients
Hypersensitivity to nivolumab or ipilimumab or any of its excipients
Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Patients with known hypersensitivity to 5-azacitdine or MK3475 or any of their excipients
Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.
Known hypersensitivity to any of the excipients of ribociclib (LEE-011)
Subjects with known hypersensitivity to study drugs or their excipients
Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in elotuzumab, formulation, or recombinant protein
Known hypersensitivity to anetumab ravtansine, study drug classes or excipients in the formulation
Patients with a known hypersensitivity to any of the investigational agents or any of the excipients of the products
History of severe hypersensitivity reactions to paclitaxel or any of its excipients.
Patient has a known hypersensitivity to any of the excipients of ribociclib, aromatase inhibitors (such as letrozole) or fulvestrant
Hypersensitivity to nivolumab or lenalidomide or any of their excipients
Hypersensitivity to ruxolitinib or any of its excipients
Known hypersensitivity to any of the excipients of ribociclib or doxorubicin
Known hypersensitivity to afatinib or its excipients
Known hypersensitivity to GT0918 or its excipients.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipients
Known hypersensitivity to letrozole or fulvestrant, or any of its excipients, or to any palbociclib excipients
Known hypersensitivity to exemestane or its excipients
Known hypersensitivity to nintedanib, any other trial drug, or their excipients
Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant protein
Known history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and dextran 40)
Patient has known hypersensitivity to any of the excipients of ribociclib
Known hypersensitivity to afatinib or the excipients of any of the trial drugs
Known hypersensitivity to S-equol or any of its excipients
Patients with a known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate, apalutamide or prednisone or their excipients
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
Known allergies, hypersensitivity, or intolerance to the IP or its excipients
Has hypersensitivity to eribulin or any of the excipients
Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients
Known hypersensitivity to ASN007 or its excipients;
History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients
hypersensitivity to the active substance or to any of the excipients of study drug;
Known hypersensitivity to any of the excipients of INC280
Patients with a known hypersensitivity to BKM120 or to its excipients
Subjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.
Known hypersensitivity to MMB, its metabolites, or formulation excipients
Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product
Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab
Known hypersensitivity to irinotecan or its excipients.
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients
Patients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligible
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Known allergy or hypersensitivity to study treatment or any of the study drugs excipients.
Patient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.
Patient has a known hypersensitivity to any of the excipients of BYL719 (alpelisib)
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or any of their excipients
Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other antigen
Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients
Patient has a known hypersensitivity to any of the excipients of buparlisib
Patient has a known hypersensitivity to ribociclib or excipients of tamoxifen
Patient has known hypersensitivity to any of the excipients of ribociclib
Patients with hypersensitivity to excipients of the study drug are not eligible
Known hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcohol
Known hypersensitivity to afatinib, dasatinib, or the excipients of any of the trial drugs
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Hypersensitivity to erlotinib or alectinib or to any of the excipients.
Intolerance to the excipients of the CTL019 cell product
Subject has a history of allergy or hypersensitivity to any study drugs or their excipients.
Subject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsin
Known hypersensitivity to any excipients of tesevatinib.
Known intolerance to the study drug or any of the excipients.
Participants who had a prior exposure to trabectedin or hypersensitivity to any of the excipients will not be excluded from receiving single-agent Doxil
Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipients
Patient has a known hypersensitivity to any of the excipients of ribociclib
Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate, prednisone or their excipients
Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.
Known hypersensitivity to momelotinib, its metabolites, or formulation excipients
Hypersensitivity to the active ingredient or any of the excipients including lactose.
History of severe hypersensitivity reaction to study treatments or their excipients.
Known allergies, hypersensitivity, or intolerance to talacotuzumab and daratumumab or their excipients
Known hypersensitivity to the study drugs (GS 5829, fulvestrant or exemestane), the metabolites, or formulation excipients
Known hypersensitivity to any of the study drugs or excipients
Patient has a known hypersensitivity to Ribociclib or any of its excipients.
Known hypersensitivity to any of the study drugs or excipients
Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)
History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
Known hypersensitivity to any of the excipients of the investigational products
Known hypersensitivity to the trial drugs or to their excipients
History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
Known hypersensitivity to afatinib or letrozole or the excipients of any of the trial drugs.
Have a history of hypersensitivity to any study drugs or their excipients, or intolerance to hydration due to preexisting pulmonary or cardiac impairment, or intolerance to opioid pain medications, or a history of severe hypersensitivity to any other antigen.
Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole
Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
Known intolerance or hypersensitivity to progesterone or its excipients
Patients with a known hypersensitivity to ribociclib or everolimus or to its excipients.
Prior treatment with nintedanib (BIBF1120); known hypersensitivity to nintedanib, peanut or soya or any other trial drug, their excipients or to contrast media
Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other Antigen.
No known hypersensitivity to BIBF 1120, to its excipients or to contrast media
Patient has a known hypersensitivity to LEE011 or any of its excipients
History of hypersensitivity to any excipients in the investigational product.
Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.
Patient has a known hypersensitivity to any of the excipients of BYL719
Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients
Patients with a known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to any of the study drugs or excipients
Have a known or suspected hypersensitivity to brigatinib or its excipients.
Patients with a known hypersensitivity to BKM120 or its excipients
Have known allergies, hypersensitivity, or intolerance to AA or prednisone or their excipients
Subjects with hypersensitivity to study drugs or their excipients
Hypersensitivity to ofatumumab or its excipients
Known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies
Hypersensitivity to any of the study medications or any of the ingredients or excipients of these medications, including hypersensitivity to benzyl alcohol
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Have known allergies, hypersensitivity, or intolerance to enzalutamide or their excipients
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Patients with a known hypersensitivity to pazopanib or topotecan or to their excipients
A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.
Patients with a known hypersensitivity to BKM120 or to its excipients, or hypersensitivity to cetuximab
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Hypersensitivity to one of the trial drugs or the excipients.
Known severe hypersensitivity to tadalafil or any of the excipients of this product
Patients with a known hypersensitivity to vinorelbine or to its excipients
For Part C, have a known hypersensitivity to sorafenib or its excipients
Known intolerance to either of the study drugs (or any of the excipients)
Known allergies, hypersensitivity, or intolerance to TRC253 or its excipients.
Known intolerance to any of the study drugs (or any of the excipients)
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucil
Known hypersensitivity to idelalisib, its metabolites, or formulation excipients
A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
Known hypersensitivity to the trial drugs, to their excipients or to contrast media
Patients with a known hypersensitivity to buparlisib or to its excipients
Hypersensitivity to erlotinib, crizotinib or to any of the excipients
Known hypersensitivity to afatinib (BIBW 2992) or the excipients of any of the trial drugs
History of hypersensitivity to any of the study drugs or to any excipients.
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Known severe hypersensitivity to ketoconazole, calcitriol or any of the excipients of these products
Have known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipients
Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study
Patient has a known hypersensitivity to any of the excipients of PQR309.
Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for ENTO
Have known allergies, hypersensitivity, or intolerance to enzalutamide or niclosamide or their excipients
Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients
Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known allergy to any of the study drugs or their excipients.
Known hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known hypersensitivity to any of the study drugs or its excipients.
Known hypersensitivity to chlorambucil or any of its excipients
Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to compounds related to orteronel or to orteronel excipients
Subjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX001 or its excipients.
Known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to the active substance or to any of the excipients in the vaccine
Patients with known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen
Known allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine, dexamethasone, or their excipients
Patients with a known hypersensitivity to BKM120 or to its excipients
Known significant hypersensitivity to study drugs or excipients
Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone.
Known severe hypersensitivity to or any of the excipients of this product.
Patient has a known hypersensitivity to any of the excipients of BKM120
No known serious or severe hypersensitivity reaction to naloxegol or any of its excipients
Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;
Known intolerance to lenvatinib, everolimus (or other rapamycin derivatives), or any of the excipients
Known or suspected hypersensitivity or intolerance to fentanyl or hydromorphone or excipients in the study medications
History of hypersensitivity to any excipients in the quizartinib/placebo tablets;
Known hypersensitivity to ASN002 or its excipients;
Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product.
Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Patient has a known hypersensitivity to the administration of rolapitant or its excipients
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure)
Known intolerance to pritelivir and/or foscarnet or any of the excipients.
Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known intolerance to study drug (or any of the excipients).
